

RECEIVED

JUN 21 2001

TECH. CENTER 1-800-290-2900

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Director for Patents, Washington, D.C. 20231 on the date shown below.

Date: June 11, 2001

By:

Kay L. Gaviglio

PATENT

Docket No. GC527C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)

David Estell & Fiona Harding)

Group Art Unit: 1644

Serial No.: 09/500,135)

Examiner: D Saunders

Filed: February 8, 2000)

For: MUTANT PROTEINS HAVING)
LOWER ALLERGENIC RESPONSE)
IN HUMANS AND METHODS)
FOR CONSTRUCTING,)
IDENTIFYING AND PRODUCING)
SUCH PROTEINS)

TRANSMITTAL LETTER

Assistant Director for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated May 9, 2001, enclosed please find the following documents: Preliminary Amendment and Response to Restriction Requirement, Statement of Sameness, Paper Copy of Sequence Listings, and disk.


The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC527C1). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: June 11, 2001


Susan Faris
Registration No. 41,739

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304
Tel: 650-846-7609
Fax: 650-845-6504



RECEIVED

JUN 21 2001

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage for first class mail in an envelope addressed to the Assistant Director for Patents, Washington, D.C. 20231, on the date shown below.

Date: June 11, 2001

By:

Kay L. Gaviglio

PATENT

Docket No. GC527-C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
David Estell & Fiona Harding) Group Art Unit: 1644
Serial No.: 09/500,135) Examiner: Saunders, D
Filed: February 8, 2000)
For: Mutant Proteins having Lower)
Allergenic Response in Humans)
and Methods for Constructing,)
Identifying and Producing such)
Proteins)

PRELIMINARY AMENDMENT AND RESPONSE TO RESTRICTION
REQUIREMENT

Assistant Director for Patents
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement and Election of Species dated May 9, 2001, the Applicants respectfully elect Group 1, subgroup A. These claims are directed to polypeptides, that upon mutation, render a polypeptide of interest less immunogenic. For the convenience of the Examiner, the pending claims are attached as Appendix I.

In the Claims.

Please cancel claims 4, 6 and 15 and enter the following amended claims.

1. (Once amended) A variant of a polypeptide of interest, wherein said polypeptide of interest is selected from the group consisting of a cellulase, lipase, endoglucosidase H, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase, and a protease, and said polypeptide of interest comprises a T-cell epitope, wherein